Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy
- PMID: 33393059
- DOI: 10.1007/s43440-020-00200-4
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy
Abstract
Background: Electroconvulsive therapy (ECT) is often recommended for major depressive disorder (MDD) for those who do not respond to the first and second antidepressant trials. A combination of two therapies could improve antidepressant efficacy. Thus, this study aimed to investigate the synergistic effects of ECT combined to antidepressants with a different mechanism of action.
Methods: Rats were treated once a day, for five days with ketamine (5 mg/kg), fluoxetine (1 mg/kg), and bupropion (4 mg/kg) alone or in combination with ECT (1 mA; 100 V). After, oxidative damage and antioxidant capacity were assessed in the prefrontal cortex (PFC) and hippocampus, and pro-inflammatory cytokines levels were evaluated in the serum.
Results: ECT alone increased lipid peroxidation in the PFC and hippocampus. In the PFC of rats treated with ECT in combination with fluoxetine and bupropion, and in the hippocampus of rats treated with ECT combined with ketamine and bupropion there was a reduction in the lipid peroxidation. The nitrite/nitrate was increased by ECT alone but reverted by combination with ketamine in the hippocampus. Superoxide dismutase (SOD) was increased by ECT and maintained by fluoxetine and bupropion in the PFC. ECT alone increased interleukin-1β (IL-1β) and the administration of ketamine was able to revert this increase showing a neuroprotective effect of this drug when in combination with ECT.
Conclusion: The treatment with ECT leads to an increase in oxidative damage and alters the immunological system. The combination with ketamine was able to protect against oxidative damage and the immunological response induced by ECT.
Keywords: Antidepressant; Electroconvulsive therapy; Ketamine; Major depressive disorder; Neuroinflammation; Oxidative stress.
References
-
- World Health Organization. Depression and other common mental disorders: global health estimates. 2017. p. 1–21.
-
- Adaikkan C, Taha E, Barrera I, David O, Rosenblum K. Calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways mediate the antidepressant action of ketamine. Biol Psychiatry. 2018;84(1):65–75. - PubMed
-
- Sartorius N. The economic and social burden of depression. J Clin Psychiatry. 2001;62(Suppl 15):8–11. - PubMed
-
- Carvalho AF, Berk M, Hyphantis TN, McIntyre RS. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom. 2014;83(2):70–88. - PubMed
-
- Depression in adults: recognition and management. National Institute for Health and Care Excellence (UK); 2014.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous